Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 7;8(2):131–136. doi: 10.1016/j.apsb.2018.01.012

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 2 — ARV drugs in the pipeline for the next 10 years. (A) Rilpivirine hydrochloride (Edurant; TMC278 hydrochloride, C₂₂H₁₉ClN₆), a second-generation NNRTI. (B) Cabrotegravir (S/GSK1265744 or GSK744, C₁₉H₁₇F₂N₃O₅), an integrase inhibitor. (C) Fostemsavir, BMS-663068, C₂₅H₂₆N₇O₈P), the phosphonooxymethyl prodrug of BMS-626529, a novel small-molecule attachment inhibitor. (D) Temsavir (BMS-626529, C24H23N7O4), a novel small-molecule attachment inhibitor. (E) Bevirimat, BVM (MPC-4326, PA-457, C₃₆H₅₆O₆), the first maturation inhibitor. (F) BMS-955176 (C₄₂H₆₂N₂O₄S), the second generation HIV maturation inhibitor.